Home > Insider Trading > Filing (0001181431-11-023253)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
732485	Genzyme Corp	GENZ	Biological Products, (No Disgnostic Substances) (2836)	061047163

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1121404	Sanofi-Aventis	174, Avenue De France Paris I0 75013		No	No	Yes	No
1501770	Gc Merger Corp.	55 Corporate Drive Bridgewater NJ 08807		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.01 Par Value	Acquisiton	2011-04-06	3,947,680	$0.00	187,986,225	No	4	P	Indirect	By GC Merger Corp.
Common Stock, $0.01 Par Value	Acquisiton	2011-04-07	44,891,208	$0.00	232,877,433	No	4	P	Indirect	By GC Merger Corp.
Common Stock, $0.01 Par Value	Acquisiton	2011-04-08	4,435,393	$0.00	237,312,826	No	4	P	Indirect	By GC Merger Corp.
Common Stock, $0.01 Par Value	Acquisiton	2011-04-08	16,245,894	$76.33	253,558,720	No	4	P	Indirect	By GC Merger Corp.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	By GC Merger Corp.
No	4	P	Indirect	By GC Merger Corp.
No	4	P	Indirect	By GC Merger Corp.
No	4	P	Indirect	By GC Merger Corp.

Footnotes

Reflects shares purchased in an exchange offer.
On April 6, 2011, these shares of Genzyme Corporation ("Genzyme") common stock were exchanged for cash and a contingent value right (each, a "CVR") pursuant to GC Merger Corp.'s ("Purchaser") offer to exchange each issued and outstanding share of Genzyme common stock for $74.00 in cash and one CVR. The closing price of Genzyme common stock on April 5, 2011 was $76.33.
The shares are held by Purchaser. The Purchaser is a direct, wholly-owned subsidiary of sanofi-aventis ("Parent"). The shares may also be deemed to be indirectly beneficially owned by Parent.
On April 7, 2011, these shares of Genzyme common stock were exchanged for cash and one CVR pursuant to Purchaser's offer to exchange each issued and outstanding share of Genzyme common stock for $74.00 in cash and one CVR. The closing price of Genzyme common stock on April 6, 2011 was 76.38.
On April 8, 2011, these shares of Genzyme common stock were exchanged for cash and one CVR pursuant to Purchaser's offer to exchange each issued and outstanding share of Genzyme common stock for $74.00 in cash and one CVR. The closing price of Genzyme common stock on April 7, 2011 was 76.33.
Reflects shares acquired by Purchaser pursuant to the exercise of the "top-up" option provided for in the Agreement and Plan of Merger, dated as of February 16, 2011 among Parent, Purchaser and Genzyme.